|Traded as||FWB: EVT|
|Revenue||€87,3 million (12/2012)|
Evotec AG is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. It operates worldwide providing "the highest quality stand-alone and integrated drug discovery solutions", covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer disease. In the fiscal year 2012, Evotec generated revenues of € 87,265 m and has 670 employees at the end of September 2013.
Since 28 October 2009 the company is listed in the TecDAX index.
Evotec BioSystems GmbH was founded in Hamburg, Germany in 1993. Among the founders were Nobel Laureate Professor Manfred Eigen, Dr Karsten Henco, Dr Ulrich Aldag, Dr Freimut Leidenberger, Dr Heinrich Schulte, Professor Rudolf Rigler and Dr Charles Weissmann.
In the first years the company established collaborations with international pharma companies like Novartis and SmithKlineBeecham to develop a High-Throughput Screening System (EVOscreen®). In 1999 Evotec Biosystems went public (Frankfurt Stock Exchange: EVT) and merged one year later with the British company Oxford Asymmetry International plc, which offers chemical services for biotech and pharma companies and forms Evotec OAI (in 2005 the name changes to Evotec AG).
In 2002 the company was divided into two business parts, namely “Discovery and Development Services“ and “Tools and Technologies“. In this year Evotec Technologies GmbH was founded.
In 2006 Evotec Technologies was sold to Perkin Elmer, to focus on its core business, the discovery and development of new pharmaceutical drugs. In 2008 Evotec acquired Renovis, an US biotech company and was listed on Nasdaq. One year later Evotec voluntarily delisted its American Depository Shares from the NASDAQ stock market to concentrate its share trading on the re-entered TecDAX platform and reduce associated costs. Additionally Evotec took over 70% of Indian Research Support International Limited (RSIPL), a company providing organic synthesis and a zebrafish screening-platform from Summit Corporation.
In 2010 the company acquired DeveloGen AG, a company focused on novel therapies for metabolic disorders, e.g. diabetes. In 2011 Evotec acquired two companies; Kinaxo Biotechnologies GmbH, a Munich based, privately owned biotech company. Kinaxo's capabilities comprise a combination of technologies improving drug development across the entire pharma value chain. Furthermore Evotec took over the compound management business from Biofocus, a subsidiary of the Galapagos group. Effective as of 01 January 2013, Evotec acquired CCS Cell Culture Service GmbH, a Hamburg-based company which supports the cell culture needs of biotech and pharmaceutical companies on a worldwide basis. In summer 2013, Evotec announced that it will close its Indian operations.
Drug discovery alliances
- Boehringer Ingelheim (oncology, pain, inflammation, insulin resistance)
- CHDI (CNS, Huntington disease)
- MedImmune/Astra Zenenca (diabetes; biologicals)
- Novartis (CNS, pain)
- Roche (neurology)
- UCB (CNS, immunology)
- Janssen (diabetes, neurology)
- Bayer (endometriosis)
- Chem Bridge Corporation
- Diamond Light Source
- Hypha Discovery
- PsychoGenics Inc.
- IR Pharma
- HTS (High-Throuput-Screening)
- NMR (nuclear magnetic resonance)
- in vitro & in vivo biology
- Chemical proteomics
- Metabolic diseases
- Regenerative medicine
- Compound management
- Compound QC and storage
- Medicinal chemistry
- Structural biology
Management and Supervisory Board
- Dr Werner Lanthaler (Chief Executive Officer)
- Colin Bond (Chief Financial Officer)
- Dr Cord Dohrmann (Chief Scientific Officer)
- Dr Mario Polywka (Chief Operating Officer)
- Dr Walter Wenninger (Chairman)
- Roland Oetker
- Dr Hubert Birner
- Dr Claus Braestrup
- Prof Dr Andreas Pinkwart
- Mary C. Tanner
- Evotec AG: Press Release: Evotec OAI Announces AGM Approval of Capital Increase and New Supervisory Board Structure, 7 June 2005, Retrieved 21 September 2011
- Evotec OAI: Annual Report 2002
- Evotec AG: Annual Report 2009